CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells - PubMed (original) (raw)
CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells
S P Lee et al. J Immunol. 2000.
Abstract
Undifferentiated nasopharyngeal carcinoma (NPC) is latently infected with EBV and expresses a restricted number of viral proteins. Studies in healthy virus carriers have demonstrated that at least some of these proteins can act as targets for HLA class I-restricted CTLs. Therefore we have explored the possibility of a CTL-based therapy for NPC by characterizing EBV-specific CTL responses in 10 newly diagnosed NPC cases and 21 healthy virus carriers from Southeast Asia. Using the autologous EBV-transformed lymphoblastoid cell line, virus-specific CTL were reactivated in vitro from PBMC, cloned, and screened for cytotoxicity against target cells expressing individual EBV proteins from recombinant vaccinia vectors. EBV-specific CTLs were identified in 6 of 10 patients and 14 of 21 controls and mainly targeted the EBV nuclear Ag 3 (EBNA3) family of viral latent proteins. However, in 3 of 10 patients and 11 of 21 controls, CTLs specific for the NPC-associated protein LMP2 were also detected, albeit at low frequency. EBV-specific CTLs were detected in tumor biopsy material obtained from 3 of 6 of the patients, indicating that functional CTL are present at the tumor site, but none was specific for tumor-associated viral proteins. To assess the Ag-presenting function in NPC we studied two NPC-derived cell lines (C15 and c666.1) and demonstrated that both were capable of processing and presenting endogenously synthesized protein to HLA class I-restricted CTL clones. Overall, our data provide a sound theoretical basis for therapeutic strategies that aim to boost or elicit LMP2-specific CTL responses in NPC patients.
Similar articles
- Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S. Comoli P, et al. J Clin Oncol. 2005 Dec 10;23(35):8942-9. doi: 10.1200/JCO.2005.02.6195. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204009 Clinical Trial. - Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB. Lee SP, et al. J Immunol. 1997 Apr 1;158(7):3325-34. J Immunol. 1997. PMID: 9120290 - T cell recognition of Epstein-Barr virus associated lymphomas.
Rickinson AB, Murray RJ, Brooks J, Griffin H, Moss DJ, Masucci MG. Rickinson AB, et al. Cancer Surv. 1992;13:53-80. Cancer Surv. 1992. PMID: 1330300 Review. - Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.
Rickinson AB, Moss DJ. Rickinson AB, et al. Annu Rev Immunol. 1997;15:405-31. doi: 10.1146/annurev.immunol.15.1.405. Annu Rev Immunol. 1997. PMID: 9143694 Review.
Cited by
- The B subunit of Escherichia coli heat-labile enterotoxin enhances CD8+ cytotoxic-T-lymphocyte killing of Epstein-Barr virus-infected cell lines.
Ong KW, Wilson AD, Hirst TR, Morgan AJ. Ong KW, et al. J Virol. 2003 Apr;77(7):4298-305. doi: 10.1128/jvi.77.7.4298-4305.2003. J Virol. 2003. PMID: 12634387 Free PMC article. - CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
Lin X, Gudgeon NH, Hui EP, Jia H, Qun X, Taylor GS, Barnardo MC, Lin CK, Rickinson AB, Chan AT. Lin X, et al. Cancer Immunol Immunother. 2008 Jul;57(7):963-75. doi: 10.1007/s00262-007-0427-8. Cancer Immunol Immunother. 2008. PMID: 18094968 Free PMC article. - Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma.
Liu X, Shen H, Zhang L, Huang W, Zhang S, Zhang B. Liu X, et al. NPJ Precis Oncol. 2024 May 16;8(1):101. doi: 10.1038/s41698-024-00601-1. NPJ Precis Oncol. 2024. PMID: 38755255 Free PMC article. Review. - Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.
Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT. Hui EP, et al. Cancer Res. 2013 Mar 15;73(6):1676-88. doi: 10.1158/0008-5472.CAN-12-2448. Epub 2013 Jan 24. Cancer Res. 2013. PMID: 23348421 Free PMC article. Clinical Trial. - Sporadic EBV-associated lymphoepithelial salivary gland carcinoma with EBV-positive low-grade myoepithelial component.
Herbst H, Niedobitek G. Herbst H, et al. Virchows Arch. 2006 May;448(5):648-54. doi: 10.1007/s00428-005-0109-x. Epub 2006 Mar 1. Virchows Arch. 2006. PMID: 16508782
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials